Lenzetto

Estradiol hemihydrate, the active ingredient in Lenzetto, is an estrogen presented as a transdermal patch for transdermal use. It treats menopausal vasomotor symptoms, addresses estrogen deficiency in postmenopausal women, and helps prevent osteoporosis.

GNH USA supplies Lenzetto as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with manufacturing aligned to EU standards, rigorous quality control, and reliable global logistics and regulatory support.

Lenzetto, an estrogen transdermal system, is used to manage conditions related to low estrogen levels.

- Menopausal vasomotor symptoms: reduces frequency and severity of hot flashes and night sweats. - Estrogen deficiency in postmenopausal women: restores hormonal balance to alleviate associated symptoms. - Prevention of osteoporosis: maintains bone mineral density and lowers fracture risk.

Common and serious adverse reactions have been reported with transdermal estradiol therapy.

Common Side Effects: - Skin irritation at the patch site - Breast tenderness or enlargement - Headache - Nausea - Mood changes - Weight gain

Serious or Rare Side Effects: - Venous thromboembolism (deep vein thrombosis, pulmonary embolism) - Stroke or transient ischemic attack - Myocardial infarction - Severe allergic reaction (anaphylaxis) - Endometrial hyperplasia or carcinoma - Hepatic dysfunction

Before prescribing Lenzetto, clinicians should consider several precautionary measures.

- Cardiovascular assessment: evaluate risk of thromboembolic events. - History of hormone‑sensitive cancers: review before use. - Liver function: monitor in patients with hepatic impairment. - Breast tenderness: counsel patients about possible changes. - Application site care: rotate patch placement to minimize irritation. - Store at room temperature: keep in original packaging, protect from moisture and direct heat.

Estradiol hemihydrate may interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Combined oral contraceptives: increased estrogen exposure. - Anticoagulants (e.g., warfarin): heightened bleeding risk. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise estradiol levels.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: possible blood pressure changes. - Thyroid hormone replacement: may require dose adjustment.